2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2886

Prevalence of Systemic Lupus Erythematosus in the United States: Preliminary Estimates from a Meta-Analysis of the Centers for Disease Control and Prevention Lupus Registries
Abstract Number: 2072

Prevalence of Thyroid Dysfunction with Therapeutic Indication in Patients with Rheumatological Diseases
Abstract Number: 2306

Prevalent and Incident Multimorbidity in Rheumatoid Arthritis: A Population-Based Cohort Study
Abstract Number: 1549

Primary 1-Year Data of Ixekizumab in Biologic Disease-Modifying Anti-rheumatic Drug-Naïve Patients with Radiographic Axial Spondyloarthritis Including Data in Patients Rerandomized from Adalimumab to Ixekizumab
Abstract Number: 352

Primary Hyperparathyroidism Is Associated with a Higher Level of Serum Uric Acid: A Systematic Review and Meta-analysis
Abstract Number: 1472

Primary Sjögren’s Syndrome and Development of Another Connective Tissue Disease During Follow-up
Abstract Number: 454

Principal Component Analysis Identifies Unique Sub-Populations in Rheumatoid Arthritis Using a Combination of Serological Biomarkers: A Cross Sectional Study
Abstract Number: 2149

Principal Components Analysis as a Tool to Identify Lesional Skin Patterns in Cutaneous Lupus Erythematosus
Abstract Number: 703

Prior Knowledge Feature Reduction Improves Performance in a Machine Learning Model of Systemic Lupus Erythematosus Flare Status Using Serum Proteomics
Abstract Number: 1085

Probiotic Use and Psoriatic Arthritis Disease Activity
Abstract Number: 481

Production of IL17A in Synovial Tissue Correlates with MRI RAMRIS Scores in ACPA Positive Early Rheumatoid Arthritis
Abstract Number: 1056

Profibrotic Macrophage Activation in Systemic Sclerosis Is Dependent on the Mechanosensing MRTF-A Pathway
Abstract Number: 2301

Profile of Renal Function in Patient Suffering from Rheumatoid Arthritis
Abstract Number: 2705

Profiling Behavioral and Psychological Symptoms in Children with Spondyloarthritis and Polyarthritis
Abstract Number: 2558

Profiling of Gene Expression, Immune Cell Subtypes, and Circulating Protein Biomarkers in Systemic Lupus Erythematosus Patients Treated with the Selective Immunoproteasome Inhibitor, KZR-616

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].